Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Inhibikase Therapeutics Inc IKT

Healthcare Biotechnology
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease... see more

Recent & Breaking News (NDAQ:IKT)

Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023

PR Newswire May 8, 2023

Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference

PR Newswire May 4, 2023

Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease

PR Newswire April 26, 2023

Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase

PR Newswire April 21, 2023

Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity

PR Newswire March 31, 2023

Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023

PR Newswire March 23, 2023

Inhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders

PR Newswire March 21, 2023

Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023

PR Newswire March 16, 2023

Inhibikase Therapeutics Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro

PR Newswire March 15, 2023

Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy

PR Newswire March 8, 2023

Inhibikase Therapeutics to Present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit

PR Newswire February 15, 2023

Inhibikase Therapeutics Announces Closing of $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules

PR Newswire January 27, 2023

Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules

PR Newswire January 25, 2023

Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders

PR Newswire January 25, 2023

Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease

PR Newswire January 25, 2023

Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro

PR Newswire December 12, 2022

Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs

PR Newswire December 7, 2022

Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference

PR Newswire November 22, 2022

Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity

PR Newswire November 14, 2022

Inhibikase Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022

PR Newswire November 8, 2022